VNDA - Vanda Pharmaceuticals Inc Stock Price, Fair Value and News

4.56USD-0.07 (-1.51%)Delayed

Market Summary

USD4.56-0.07

Delayed

-1.51%

VNDA Stock Price

View Fullscreen

VNDA RSI Chart

VNDA Valuation

Market Cap

262.4M

Price/Earnings (Trailing)

104.57

Price/Sales (Trailing)

1.36

EV/EBITDA

17.43

Price/Free Cashflow

21.13

VNDA Price/Sales (Trailing)

VNDA Profitability

EBT Margin

3.29%

Return on Equity

0.46%

Return on Assets

0.39%

Free Cashflow Yield

4.73%

VNDA Fundamentals

VNDA Revenue

Revenue (TTM)

192.6M

Rev. Growth (Yr)

-29.79%

Rev. Growth (Qtr)

16.63%

VNDA Earnings

Earnings (TTM)

2.5M

Earnings Growth (Yr)

-134.98%

Earnings Growth (Qtr)

-1.9K%

Breaking Down VNDA Revenue

Last 7 days

-13.0%

Last 30 days

17.8%

Last 90 days

20.3%

Trailing 12 Months

-27.2%

How does VNDA drawdown profile look like?

VNDA Financial Health

Current Ratio

4.94

VNDA Investor Care

Shares Dilution (1Y)

1.32%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	256.7M	238.4M	211.9M	192.6M
2022	266.2M	262.7M	257.9M	254.4M
2021	252.8M	258.5M	268.3M	268.7M
2020	237.5M	240.6M	241.4M	248.2M
2019	197.2M	208.9M	219.3M	227.2M
2018	171.3M	176.6M	184.4M	193.1M
2017	150.2M	156.2M	159.1M	165.1M
2016	121.0M	129.5M	139.6M	146.0M
2015	49.2M	75.2M	98.2M	109.9M
2014	33.3M	26.5M	23.1M	34.5M
2013	32.7M	32.6M	33.0M	33.9M
2012	31.9M	32.9M	33.2M	32.7M
2011	30.8M	29.9M	30.7M	31.3M
2010	0	14.9M	25.3M	35.7M
2009	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vanda Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	birznieks gunther	sold	-35,884	4.1322	-8,684	svp, business development
Mar 05, 2024	wijkstrom joakim	sold	-38,830	4.2074	-9,229	svp, chief marketing officer
Mar 05, 2024	moran kevin patrick	sold	-37,410	4.2025	-8,902	svp, cfo & treasurer
Mar 05, 2024	williams timothy	sold	-37,395	4.1825	-8,941	svp & general counsel
Mar 05, 2024	polymeropoulos mihael hristos	sold	-100,273	4.1285	-24,288	president and ceo
Mar 04, 2024	birznieks gunther	sold	-37,494	4.2964	-8,727	svp, business development
Mar 04, 2024	wijkstrom joakim	sold	-33,090	4.4133	-7,498	svp, chief marketing officer
Mar 04, 2024	williams timothy	sold	-35,916	4.4086	-8,147	svp & general counsel
Mar 04, 2024	polymeropoulos mihael hristos	sold	-131,066	4.2438	-30,884	president and ceo
Mar 04, 2024	moran kevin patrick	sold	-25,982	4.4812	-5,798	svp, cfo & treasurer

Which funds bought or sold VNDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	CGC Financial Services, LLC	unchanged	-	-5.00	206	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.57	-13,000	8,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-3,060	129,136	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	-1,100	41,100	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	21,000	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-36.1	-400,262	659,536	-%
Apr 18, 2024	Diversified Trust Co	added	2.88	508	257,092	0.01%
Apr 15, 2024	Security National Bank	sold off	-100	-625	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-993,202	-	-%
Apr 11, 2024	Profit Investment Management, LLC	reduced	-43.4	-737,206	905,531	0.51%

Are Funds Buying or Selling VNDA?

Are funds buying VNDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VNDA

No. of Funds

Unveiling Vanda Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	6.40%	3,681,125	SC 13G/A
Feb 13, 2024	vanguard group inc	6.01%	3,456,087	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	3.4%	1,967,985	SC 13G/A
Jan 23, 2024	blackrock inc.	14.5%	8,346,367	SC 13G/A
Jan 22, 2024	state street corp	2.13%	1,228,096	SC 13G/A
Oct 06, 2023	blackrock inc.	11.8%	6,759,117	SC 13G/A
Feb 14, 2023	palo alto investors lp	1.42%	1,087,064	SC 13G/A
Feb 14, 2023	macquarie group ltd	2.34%	1,323,547	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.09%	2,889,425	SC 13G/A
Feb 10, 2023	dimensional fund advisors lp	5.0%	2,853,832	SC 13G

Recent SEC filings of Vanda Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	8-A12B	8-A12B
Apr 17, 2024	8-K	Current Report
Apr 03, 2024	8-K	Current Report
Mar 07, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Vanda Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Vanda Pharmaceuticals Inc News

Latest updates

Vanda Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	16.6%	45.00	39.00	46.00	62.00	64.00	65.00	64.00	60.00	68.00	70.00	68.00	63.00	68.00	60.00	62.00	58.00	61.00	59.00	59.00	48.00	53.00
Costs and Expenses	16.9%	52.00	45.00	49.00	60.00	58.00	61.00	61.00	68.00	59.00	59.00	56.00	52.00	57.00	53.00	53.00	58.00	57.00	49.00	49.00	50.00	44.00
S&GA Expenses	-4.7%	24.00	25.00	28.00	36.00	33.00	30.00	33.00	41.00	33.00	32.00	28.00	30.00	36.00	34.00	34.00	37.00	37.00	30.00	31.00	31.00	25.00
R&D Expenses	46.6%	24.00	17.00	17.00	19.00	18.00	25.00	21.00	21.00	19.00	20.00	20.00	16.00	15.00	12.00	13.00	16.00	13.00	11.00	11.00	13.00	13.00
EBITDA Margin	-57.1%	0.04*	0.09*	0.10*	0.10*	0.05*	0.04*	0.06*	0.10*	0.16*	0.17*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Income Taxes	343.3%	1.00	-0.30	1.00	2.00	3.00	2.00	1.00	-1.13	1.00	3.00	3.00	2.00	3.00	2.00	2.00	1.00	2.00	-88.10	0.00	0.00	-0.04
Earnings Before Taxes	-1284.2%	-1.66	-0.12	3.00	6.00	10.00	5.00	4.00	-7.56	9.00	11.00	13.00	10.00	11.00	8.00	11.00	1.00	6.00	12.00	12.00	-0.60	10.00
EBT Margin	-60.4%	0.03*	0.08*	0.10*	0.10*	0.04*	0.04*	0.06*	0.09*	0.16*	0.17*	0.16*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	-1851.8%	-2.40	0.00	2.00	3.00	7.00	3.00	3.00	-6.43	7.00	8.00	10.00	9.00	8.00	6.00	9.00	0.00	4.00	100	12.00	-0.61	10.00
Net Income Margin	-76.6%	0.01*	0.06*	0.06*	0.06*	0.02*	0.03*	0.04*	0.07*	0.12*	0.13*	0.13*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-92.1%	-3.98	-2.07	-13.27	32.00	9.00	13.00	5.00	4.00	26.00	9.00	19.00	9.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.1%	648	642	642	645	634	622	609	604	594	580	568	543	533	516	507	489	484	474	372	351	332
Current Assets	-19.3%	433	537	534	534	519	507	497	492	478	462	447	421	409	390	381	361	354	280	316	306	299
Cash Equivalents	-25.9%	136	183	150	354	135	49.00	58.00	67.00	53.00	51.00	57.00	72.00	62.00	57.00	95.00	65.00	46.00	39.00	47.00	34.00	62.00
Inventory	34.9%	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-4.3%	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	5.1%	104	99.00	102	109	107	106	101	101	89.00	86.00	86.00	76.00	80.00	75.00	75.00	72.00	73.00	74.00	76.00	73.00	57.00
Current Liabilities	3.4%	88.00	85.00	87.00	94.00	91.00	93.00	88.00	91.00	74.00	72.00	72.00	62.00	66.00	61.00	62.00	59.00	60.00	60.00	63.00	59.00	53.00
Shareholder's Equity	0.3%	545	543	540	536	527	516	509	502	505	493	481	468	453	441	432	416	411	401	297	278	275
Retained Earnings	-1.6%	-155	-152	-153	-154	-157	-164	-168	-170	-164	-171	-179	-188	-197	-205	-211	-220	-220	-224	-325	-336	-336
Additional Paid-In Capital	0.5%	700	697	694	691	686	682	678	674	669	664	660	656	650	646	642	636	631	626	622	615	612
Shares Outstanding	0.0%	58.00	58.00	57.00	57.00	57.00	57.00	56.00	56.00	56.00	56.00	56.00	55.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	369	-	-	-	601	-	-	-	1,169	-	-	-	610	-	-	-	731	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-82.0%	-3,732	-2,050	-13,220	31,803	9,416	12,837	5,685	4,046	26,607	9,397	19,017	9,193	19,302	9,374	24,006	-907	9,791	5,998	20,515	9,643	15,263
Share Based Compensation	3.3%	3,273	3,167	3,249	4,351	3,783	3,888	3,830	4,778	3,774	3,951	3,740	3,909	3,212	3,135	3,069	3,944	3,668	3,407	3,101	3,282	2,922
Cashflow From Investing	-223.9%	-43,783	35,327	-190,894	187,294	75,428	-21,777	-14,592	10,866	-25,998	-16,588	-34,181	71.00	-16,686	-47,845	2,732	20,300	-6,230	-13,874	-11,754	-36,451	-15,804
Cashflow From Financing	-	-	-	-	-	605	4.00	125	-	1,041	371	289	1,849	1,432	123	3,600	479	2,116	558	3,411	179	792

VNDA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Net product sales	$ 192,640	$ 254,382	$ 268,682
Total revenues	192,640	254,382	268,682
Operating expenses:
Cost of goods sold excluding amortization	14,796	24,282	25,629
Research and development	76,823	85,770	75,363
Selling, general and administrative	112,883	136,485	124,047
Intangible asset amortization	2,090	1,516	1,478
Total operating expenses	206,592	248,053	226,517
Income (loss) from operations	(13,952)	6,329	42,165
Other income	20,291	4,971	199
Income before income taxes	6,339	11,300	42,364
Provision for income taxes	3,830	5,025	9,212
Net income	$ 2,509	$ 6,275	$ 33,152
Net income per share:
Basic (in dollars per share)	$ 0.04	$ 0.11	$ 0.60
Diluted (in dollars per share)	$ 0.04	$ 0.11	$ 0.58
Weighted average shares outstanding:
Basic (in shares)	57,380,975	56,461,877	55,548,122
Diluted (in shares)	57,557,911	56,983,171	56,921,836

VNDA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 135,821	$ 135,029
Marketable securities	252,443	331,830
Accounts receivable, net	34,155	33,512
Inventory	1,357	1,194
Prepaid expenses and other current assets	9,170	17,727
Total current assets	432,946	519,292
Property and equipment, net	2,037	2,573
Operating lease right-of-use assets	7,103	8,400
Intangible assets, net	121,369	18,565
Deferred tax assets	75,000	74,039
Non-current inventory and other	9,985	11,378
Total assets	648,440	634,247
Current liabilities:
Accounts payable and accrued liabilities	38,460	45,551
Product revenue allowances	49,237	45,885
Total current liabilities	87,697	91,436
Operating lease non-current liabilities	7,006	8,813
Other non-current liabilities	8,827	6,800
Total liabilities	103,530	107,049
Commitments and contingencies (Notes 11 and 17)
Stockholders’ equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022, respectively	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 57,534,499 and 56,783,764 shares issued and outstanding at December 31, 2023 and 2022, respectively	58	57
Additional paid-in capital	700,274	686,235
Accumulated other comprehensive loss	(30)	(1,193)
Accumulated deficit	(155,392)	(157,901)
Total stockholders’ equity	544,910	527,198
Total liabilities and stockholders’ equity	$ 648,440	$ 634,247

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

CEO	Dr. Mihael H. Polymeropoulos M.D.
WEBSITE	vandapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	290

Vanda Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vanda Pharmaceuticals Inc? What does VNDA stand for in stocks?

VNDA is the stock ticker symbol of Vanda Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vanda Pharmaceuticals Inc (VNDA)?

As of Wed Apr 24 2024, market cap of Vanda Pharmaceuticals Inc is 262.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VNDA stock?

You can check VNDA's fair value in chart for subscribers.

What is the fair value of VNDA stock?

You can check VNDA's fair value in chart for subscribers. The fair value of Vanda Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vanda Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VNDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vanda Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VNDA is over valued or under valued. Whether Vanda Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vanda Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VNDA.

What is Vanda Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, VNDA's PE ratio (Price to Earnings) is 104.57 and Price to Sales (PS) ratio is 1.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VNDA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vanda Pharmaceuticals Inc's stock?

In the past 10 years, Vanda Pharmaceuticals Inc has provided -0.1 (multiply by 100 for percentage) rate of return.